share_log

Jin Medical International | 6-K: Report of foreign private issuer (related to financial reporting)

SEC ·  Jul 27 04:14

Summary by Futu AI

Jin Medical International Ltd. (Jin Medical), a Cayman Islands exempted company, has furnished its unaudited condensed consolidated financial statements for the six months ended March 31, 2024, as part of its current report on Form 6-K. The report, filed with the SEC for July 2024, includes detailed financial performance indicators such as revenue, gross profit and margin, operating expenses, and operating income. Jin Medical, through its China-based VIE, Changzhou Zhongjin, and subsidiaries, primarily designs and manufactures wheelchairs and living aids for the disabled, elderly, and those recovering from injuries, with a focus on wheelchairs. The majority of its products are sold to dealers in Japan and China, with a smaller number distributed to other regions. The company's revenue is primarily derived...Show More
Jin Medical International Ltd. (Jin Medical), a Cayman Islands exempted company, has furnished its unaudited condensed consolidated financial statements for the six months ended March 31, 2024, as part of its current report on Form 6-K. The report, filed with the SEC for July 2024, includes detailed financial performance indicators such as revenue, gross profit and margin, operating expenses, and operating income. Jin Medical, through its China-based VIE, Changzhou Zhongjin, and subsidiaries, primarily designs and manufactures wheelchairs and living aids for the disabled, elderly, and those recovering from injuries, with a focus on wheelchairs. The majority of its products are sold to dealers in Japan and China, with a smaller number distributed to other regions. The company's revenue is primarily derived from wheelchair sales and components, and living aids products. Key financial results for the six months ended March 31, 2024, show a 3.0% increase in revenue and a 1.6% increase in net income attributable to Jin Medical International Ltd. compared to the same period in 2023. Gross profit increased by 5.8%, while operating expenses rose by 42.5%. The company also reported a 30.6% decrease in income from operations and a 51.4% increase in income tax provision. Jin Medical's shares began trading on the Nasdaq Capital Market under the symbol 'ZJYL' on March 28, 2023, following an initial public offering. The company's cash and short-term investments have increased since September 30, 2023, and it expects to meet its working capital needs for the foreseeable future through current cash, operating activities, bank borrowings, and IPO proceeds.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.